Previously, SGLT−2 inhibition was contraindicated for patients with impaired renal function (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m2), and thus, this treatment was limited to patients with diabetes and preserved kidney function (83). This evidence concerns the gene SLC5A2 and diabetes mellitus.